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A b s t r a c t
Introduction: Patients treated within chronic total occlusions (CTO) using percutaneous coronary intervention (PCI) are at in-
creased risk of periprocedural complications.
Aim: To assess the frequency of periprocedural complications with particular emphasis on coronary artery perforations (CAPs) 
among patients treated with PCIs stratified according to CTOs and their predictors. 
Material and methods: Based on a nationwide registry (ORPKI), we analysed 535,853 patients treated with PCI between 2014 
and 2018. The study included 12,572 (2.34%) patients treated with CTO PCI. We compared CTO PCI to a non-CTO PCI group before 
and after propensity score matching (PSM). Multifactorial mixed regression models were used to assess predictors of periprocedural 
complications and CAPs which occurred within the catheterization laboratory. 
Results: Frequencies of all periprocedural complications (2.75% vs. 1.93%, p < 0.001) and CAP (0.72% vs. 0.16%, p < 0.001) 
were significantly higher in the CTO PCI group. Multifactorial regression analysis performed in the all-comers group of patients 
treated with PCI showed that PCI within CTO was related to a higher CAP rate (odds ratio (OR) = 2.18; 95% confidence interval (CI): 
1.68–2.82, p < 0.001). After PSM, we extracted 5,652 patients treated within CTO and 5,652 patients with non-CTO PCI. CTO PCI was 
also related to a higher frequency of CAPs (OR = 1.89; 95% CI: 1.11–3.31, p = 0.01). 
Conclusions: The frequency of periprocedural complications and CAPs remained stable during the assessed period of time. CTO 
PCI was confirmed to be among the predictors of increased CAP rate in the overall group of patients treated within CTO. 
Key words: chronic total occlusion, coronary artery perforations, percutaneous coronary intervention, periprocedural complications.
S u m m a r y
Despite significant technical progress, patients treated within chronic total occlusions (CTO) using percutaneous coronary 
intervention (PCI) are at increased risk of periprocedural complications. The main finding of the current study is that patients 
from the CTO PCI group presented a significantly higher frequency of periprocedural complications and coronary artery per-
forations (CAPs) in comparison to the non-CTO PCI group. The frequency of overall periprocedural complications and CAPs 
remained stable in the CTO PCI group during the assessed period of time, while in the non-CTO PCI and all-comers groups, the 
overall periprocedural complication rate significantly decreased and the CAP rate significantly increased in the all-comers group.
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Introduction
Despite significant technical progress, patients treat-
ed within chronic total occlusions (CTO) using percuta-
neous coronary intervention (PCI) are at increased risk of 
periprocedural complications [1, 2]. CTO PCI is a strong 
predictor of coronary artery perforation (CAP) in the 
all-comers group of patients treated with PCI [3]. The 
incidence of CAP during PCI is estimated at 0.1–0.84% 
[4, 5]. CAP can have life-threatening consequences which 
include tamponade, major bleeding, the need for emer-
gent cardiac surgery and in-hospital death [6, 7]. The use 
of PCI in higher risk subgroups, especially among older 
patients, has been recently increasing [8]. Parsh et al. 
reported that among 181,590 patients treated with PCI, 
625 (0.34%) suffered CAP during the PCI procedure and 
41 (6.56%) patients with perforation died before dis-
charge. While the frequency of CTO PCI cases has been 
reported to increase significantly over the last years, from 
1.6% to 2.8% of all cases, the incidence of perforation 
did not show a statistically significant trend [3]. Although 
the incidence and predictors of CAP have recently been 
studied in several large all-comers PCI series, limited 
data exist on predictors of CAP during CTO PCI [3, 9, 10]. 
CAPs in PCI occur rarely, but are more frequent during 
CTO PCI (1.4% to 4.4%) and among retrograde PCIs [6, 
7, 10]. Increased mortality at follow-up after CAP has 
been recently reported [5]. CTO PCI success rates con-
tinue to improve as new techniques and tools develop. 
The occurrence of periprocedural complications, howev-
er, continues to affect risk-benefit considerations, and is 
estimated at 3.1% in a  large meta-analysis [11]. So far, 
it has been shown that PCI within CTO in post-interven-
tional follow-up mainly improves the reduction of clinical 
symptoms of ischaemia, while it has a lesser impact on 
survival; however, a “practice-based medicine” approach 
often dominates in everyday practice rather than “evi-
dence-based medicine” [1, 6, 11].
Aim
To investigate the frequency of periprocedural com-
plications, with special insight into CAPs among patients 
treated with PCI within CTO and their predictors.
Material and methods
Study design and patient population
This retrospective analysis was performed on pro-
spectively collected data. Data for conducting the current 
study were obtained from the National Registry of Percu-
taneous Coronary Interventions (ORPKI). The registry has 
been described in previously published papers [12]. Data 
were collected from the registry between January 2014 
and December 2018. We selected 12,572 patients treat-
ed with PCI within CTO out of 535,853 patients treated 
using PCI during the analysed period. The technical as-
pects of the procedure such as the choice of access site 
(femoral or radial), culprit lesion approach (antegrade or 
retrograde), sheath and catheter size, as well as guide-
wires, microcatheters and other devices specific for CTO 
PCIs, were at the operator’s discretion. A coronary CTO 
is defined as a total occlusion in a coronary artery with 
non-collateral Thrombolysis in Myocardial Infarction 
(TIMI) flow grade 0 of at least 3-month duration [13]. 
Furthermore, the periprocedural anticoagulation and in-
dications for PCI as well as stent type also remained at 
the first operator’s discretion. Antiplatelet therapy was 
implemented according to current European Guidelines 
[14]. The protocol complied with the 1964 Declaration of 
Helsinki, and all participants provided their written in-
formed consent for the percutaneous intervention. Due 
to the retrospective nature and anonymisation of the 
collected data and registry, obtaining the consent of the 
Bioethics Committee was not required.
Endpoints of interest
Primary endpoints of interest were periprocedural 
complications, which consisted of arterial dissections, 
CAPs, cardiac arrests, deaths, allergic reactions, myo-
cardial infarctions, no-reflows, cerebral strokes and 
puncture-site bleedings. The identification of individual 
complications was left to the discretion of the operator 
and included those which occurred within the cathe-
terization laboratory. The no reflow phenomenon was 
defined when angiographic evidence of reopening of 
the occluded coronary artery and successful stent place-
ment with no evidence of flow-limiting residual stenosis 
(< 50%), dissection, vessel spasm, or thrombus burden 
was present and concomitant Thrombolysis in Myocardi-
al Infarction (TIMI) flow grade ≤ II, or a TIMI flow grade III 
with a myocardial perfusion grade 0 or I, at least 10 min 
after the end of the PCI procedure was found. Prior to 
propensity score matching (PSM), we calculated predic-
tors of overall periprocedural complications and CAPs in 
the all-comers group of patients treated with PCI. After 
PSM, we also assessed the effect of PCI within CTOs on 
the overall periprocedural complication count as well as 
other particular complications. 
Statistical analysis
Categorical variables are presented as numbers and 
percentages. Continuous variables are expressed as 
mean (standard deviation (SD)) or median (interquartile 
range (IQR)), where applicable. Normality was assessed 
via the Shapiro-Wilk test. Equality of variance was eval-
uated using Levene’s test. Differences between the two 
groups were compared using Student’s or Welch’s t-test 
depending on the equality of variances for normally dis-
tributed variables. The Mann-Whitney U test was applied 
for non-normally distributed continuous variables. Cat-
egorical variables were compared with Pearson’s c2 or 
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Fisher’s exact test if 20% of cells had an expected count 
of less than 5 (Monte Carlo simulation for Fisher’s test 
using tables of higher dimensions than 2x2). Multifacto-
rial logistic regression models were constructed to find 
predictors of all procedure-related complications and 
CAPs in the all-comers group of patients treated with 
PCI. Then, all of the baseline/demographic characteris-
tics were included in the logistic regression model via 
PSM. PSM was performed with the nearest neighbour 
algorithm. The groups were considered balanced if stan-
dardised differences for each of the analysed baseline/
demographic characteristics were lower than 10%. The 
PSM included age, body mass, diabetes, prior stroke, pri-
or myocardial infarction (MI), prior PCI, prior coronary 
artery bypass grafting (CABG), smoking status, arterial 
hypertension, kidney disease, chronic obstructive pulmo-
nary disease (COPD), vascular access, thrombectomy, ro-
tablation use, TIMI flow grade before PCI, gender, clinical 
presentation at baseline, cardiac arrest before admission 
to hospital, the use of imaging modalities (fractional flow 
reserve (FFR), intravascular ultrasound (IVUS), optical co-
herence tomography (OCT)), results of coronary artery 
angiography, type of PCI and culprit lesion. FFR was used 
to assess other borderline stenosis in target vessel (CTO 
treated with PCI) located before or behind the culprit le-
sion and measured after PCI. The effect of PCI within CTO 
on procedure-related complications was assessed using 
mixed-effect models to account for matching. Statistical 
analysis was performed using R, version 3.5.3 (R Foun-
dation for Statistical Computing, Vienna, Austria, 2019) 




Before PSM, we compared the group of 523,281 pa-
tients treated with PCI to the non-CTO culprit lesion with 
12,572 patients treated within the CTO culprit lesion. All 
complication frequencies were significantly higher among 
patients in the CTO PCI group compared to the non-CTO 
PCI group (p < 0.001, Table I). This was mainly caused by 
the significantly higher frequencies of no-reflow (p = 0.02), 
CAP (p < 0.001) and puncture-site bleeding (p < 0.001) in 
the CTO group than the non-CTO group (Table I). 
Patient characteristics stratified by CAP
Patients who experienced CAP were significantly old-
er (p = 0.02), less often males (p = 0.004) and suffered 
more frequently from arterial hypertension (p = 0.01; Ta-
ble II). 
Coronary angiography and culprit lesion 
characteristics
There were no statistically significant differences 
in the results of coronary angiography or culprit lesion 
characteristics between the CTO CAP and non-CAP CTO 
groups (Table II).
Table I. Periprocedural complications in the group of all-comers treated with PCI stratified by type of culprit 








All complications 10,462 (1.95) 10,115 (1.93) 346 (2.75) < 0.001
Number of complications: < 0.001
1 306 (2.46) 167 (2.05) 139 (3.23)
2 32 (0.26) 14 (0.17) 18 (0.42)
3 6 (0.05) 3 (0.04) 3 (0.07)
5 1 (0.01) 1 (0.01) 0 (0)
Coronary artery dissection 631 (0.14) 622 (0.14) 9 (0.11) < 0.001
Coronary artery perforation 934 (0.17) 843 (0.16) 91 (0.72) < 0.001
Cardiac arrest 3,400 (0.63) 3,317 (0.63) 83 (0.66) 0.71
Death 2,392 (0.45) 2,337 (0.45) 55 (0.44) 0.87
Allergic reaction 723 (0.13) 707 (0.14) 16 (0.13) 0.81
Myocardial infarction 550 (0.1) 537 (0.1) 13 (0.1) 0.97
No-reflow 2,852 (0.53) 2,766 (0.53) 86 (0.68) 0.02
Stroke 49 (0.01) 48 (0.01) 1 (0.01) 0.94
Puncture-site bleeding 608 (0.11) 567 (0.11) 41 (0.33) < 0.001
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Table II. Clinical characteristics, coronary angiography and culprit lesion characteristics in patients treated with 








Age [years] 66.6 ±10.3 66.6 ±10.3 68.5 ±9.9 0.02
Weight [kg] 83.2 ±16.1 83.3 ±16.7 81.4 ±14.0 0.22
Gender, males 9,427 (75.0) 9,371 (75.1) 56 (61.5) 0.004
Diabetes 3,472 (27.6) 3,445 (27.6) 27 (29.7) 0.66
Arterial hypertension 9,615 (76.5) 9,536 (76.4) 79 (86.8) 0.01
Prior stroke 492 (3.91) 485 (3.89) 7 (7.69) 0.09
Prior myocardial infarction 5,901 (46.9) 5,855 (46.9) 46 (50.5) 0.48
Prior PCI 5,979 (47.6) 5,931 (47.5) 48 (52.7) 0.32
Prior CABG 1,034 (8.2) 1,027 (8.2) 7 (7.7) 0.85
Smoking 2,711 (21.6) 2,688 (21.5) 23 (25.3) 0.39
Kidney failure 935 (7.4) 925 (7.4) 10 (11.0) 0.22
COPD 409 (3.7) 406 (3.7) 3 (3.6) 0.96
Clinical presentation of CAD: 0.62
Stable angina 6,304 (50.3) 6,257 (50.2) 47 (51.6)
Unstable angina 2,978 (23.7) 2,955 (23.7) 23 (25.3)
NSTEMI 1,615 (12.9) 1,607 (12.9) 8 (8.8)
STEMI 1,420 (11.3) 1,409 (11.3) 11 (12.1)
Others 231 (1.8) 229 (1.8) 2 (2.2)
Coronary angiography: 0.6
SVD 3,404 (40.2) 3,388 (40.2) 16 (31.4)
MVD without LMCA 4,550 (53.7) 4,518 (53.7) 32 (62.7)
MVD and LMCA 500 (5.9) 497 (5.9) 3 (5.9)
Isolated LMCA 14 (0.2) 14 (0.2) 0 (0)
Location of culprit artery:
Right coronary artery 5,814 (46) 5,776 (46.3) 38 (41.8) 0.38
Left main coronary artery  64 (0.5) 63 (31.2) 1 (33.3) 0.93
Left anterior descending 
artery
3,811 (30.2) 3,780 (30.3) 31 (34.1) 0.43
Circumflex artery 2,841 (22.5) 2,820 (22.6) 21 (23.1) 0.91
Bifurcation 162 (6.0) 161 (6.0) 1 (4.8) 0.8
Type of culprit lesion: 0.68
De-novo 10,546 (93.6) 10,464 (93.6) 82 (95.3)
Restenosis 697 (6.2) 693 (6.2) 4 (4.6)
Thrombosis 24 (0.21) 24 (0.21) 0 (0)
Data are presented as mean ± standard deviation or count (percentage); percentages reflect available study data. CABG – coronary artery bypass grafting, 
CAD – coronary artery disease, COPD – chronic obstructive pulmonary disease, CTO – chronic total occlusion, LAD – left anterior descending coronary artery, 
LMCA – left main coronary artery, MVD – multi-vessel disease, NSTEMI – non-ST segment elevation myocardial infarction, PCI – percutaneous coronary intervention, 
STEMI – ST segment elevation myocardial infarction, SVD – single-vessel disease.
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Femoral 2,271 (26.8) 2,261 (26.8) 10 (19.6)
Radial right 4,852 (57.2) 4,828 (57.3) 24 (47.1)
Radial left 1,274 (15.0) 1,257 (14.9) 17 (33.3)
Fractional flow reserve 131 (1.0) 130 (1.0) 1 (1.1) 0.95
Intravascular ultrasound 179 (1.4) 177 (1.4) 2 (2.2) 0.56
Optical coherence tomography 80 (0.6) 80 (0.6) 0 (0) 0.28
Rotablation 106 (0.8) 105 (0.84) 1 (1.1) 0.79
TIMI flow grade before PCI: 0.26
0 9,790 (78.7) 9,715 (78.7) 75 (83.3)
Other than 0 2,648 (21.3) 2,633 (21.3) 15 (16.7)
TIMI flow grade after PCI: < 0.001
0 3,913 (31.5) 3,864 (31.3) 49 (54.4)
1 682 (5.5) 675 (5.5) 7 (7.8)
2 524 (4.2) 520 (4.2) 4 (4.4)
3 7,315 (58.8) 7,285 (59.0) 30 (33.3)
Culprit artery patency after PCI: < 0.001
Present (TIMI grade 2 and 3) 7,839 (63.0) 7,805 (63.2) 34 (37.8)
Type of PCI: 0.005
Drug-eluting stent 5,645 (44.9) 5,616 (45) 29 (31.9)
Bare-metal stent 22 (0.2) 20 (0.2) 2 (2.2)
Bioresorbable stent 294 (2.3) 292 (2.3) 2 (2.2)
DCB/POBA/Failed angioplasty 6,611 (52.6) 6,553 (52.5) 58 (63.7)
Procedure-related complications 346 (2.7) 255 (2.0) 91 (100) –














Data are presented as mean ± standard deviation, median [interquartile range] or count (percentage); percentage reflects available study data. BMS – bare-metal 
stent, BRS – bioresorbable scaffold, CTO – chronic total occlusion, DCB – drug-coated balloon, DES – drug-eluting stent, FFR fractional flow reserve, IVUS – intra-
vascular ultrasound, OCT – optical coherence tomography, PCI – percutaneous coronary intervention, POBA – plain-old balloon angioplasty, TIMI – thrombolysis in 
myocardial infarction.
Procedural indices
Considering the type of PCI, significantly more patients 
in the CAP CTO group were treated without stent implanta-
tion, compared to the non-CAP CTO group (p = 0.005). These 
and other procedural indices are presented in Table III. 
Overall procedure-related complications 
When assessing the overall group of patients treated 
with PCI, all procedural complication frequencies signifi-
cantly decreased in the studied period of time (2.29% vs. 
1.98% vs. 1.89% vs. 1.81% vs. 1.86%, p < 0.001; Figure 1 A). 
A similar trend was observed in the non-CTO PCI group 
(2.26% vs. 1.96% vs. 1.87% vs. 1.79% vs. 1.84%, p < 
0.001; Figure 1 B). However, in the CTO PCI group, the fre-
quency of procedure-related complications, with the ex-
ception of the year 2014, remained at a stable level and 
did not change significantly (3.84% vs. 2.49% vs. 2.56% 
vs. 2.73% vs. 2.58%, p = 0.12; Figure 1 C). 
Coronary artery perforations 
The frequency of CAPs in the overall group of patients 
treated with PCI during the assessed period demonstrat-
ed a statistically significant increase in consecutive years 
(0.15% vs. 0.17% vs. 0.19% vs. 0.16% vs. 0.2%, p = 0.02, 
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Figure 2 A), whereas in the non-CTO PCI group of patients, 
the frequency of CAPs did not show a statistically signif-
icant change (0.14% vs. 0.16% vs. 0.17% vs. 0.15% vs. 
0.18%, p = 0.1, Figure 2 B). Also, there were no statisti-
cally significant changes in the frequency of CAPs in the 
CTO PCI group, although it did tend to increase (0.5% vs. 
0.64% vs. 0.78% vs. 0.74% vs. 0.85%, p = 0.18, Figure 2 C). 
Predictors of all complications 
Before PSM, multifactorial logistic regression analysis 
performed in the overall group of patients treated with 
PCI revealed the following factors to be among signifi-
cant predictors of all complication frequencies: age, dia-
betes mellitus, COPD, kidney disease, smoking, vascular 
access, prior PCI, MI, and stroke, patency of target coro-
nary artery before PCI, type of PCI, type of culprit lesion 
and PCI within CTO culprit lesion (Figure 3 A). 
Predictors of coronary artery perforations 
Prior to PSM, via multifactorial logistic regression 
analysis performed in the overall group of patients treat-
ed with PCI, the following factors were found to be sig-
nificant predictors of CAPs: age, kidney disease, smoking, 
prior cerebral stroke, patency of target artery before PCI, 
no-reflow phenomenon, type of PCI and PCI within CTO 
culprit lesion (Figure 3 B). 
Procedure-related complications stratified 
according to CTO PCI after PSM
After PSM, we extracted 5,652 patients treated with-
in CTO and 5,652 patients with non-CTO PCI. Multifacto-
rial analysis revealed that PCI within CTO was statistical-
ly significantly related to the higher frequency of CAPs 
(odds ratio (OR) = 1.89; 95% confidence interval (CI): 
1.11–3.31, p = 0.01), while being less frequently correlat-
ed with deaths (OR = 0.44; 95% CI: 0.30–0.63, p < 0.001), 
no-reflow (OR = 0.69; 95% CI: 0.48–0.98, p = 0.03), dis-
sections (OR = 0.13; 95% CI: 0.03–0.37, p < 0.001) and all 
complications (OR = 0.67; 95% CI: 0.55–0.82, p < 0.001). 
Discussion 
The main finding of the current study is that patients 
from the CTO PCI group presented significantly higher 
frequency of periprocedural complications and CAPs in 
comparison to the non-CTO PCI group. The frequency of 
overall periprocedural complications and CAPs remained 
stable in the CTO PCI group during the assessed period, 
while in the non-CTO PCI and all-comers groups, the 
overall periprocedural complication rate significantly de-
creased and the CAP rate significantly increased in the 
all-comers group. Patients from the CAP CTO group were 
significantly older, more often females, and more fre-
quently treated from radial access in comparison to the 
Figure 1. Frequency distribution of all proce-
dure-related complications in consecutive years 
between 2014 and 2018 among selected groups 
of patients. A – All-comers group of patients treat-
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non-CAP CTO group. Also, the effectiveness of PCIs in the 
CAP-CTO group, compared to the non-CAP CTO PCI group, 
assessed as patency of the coronary artery by TIMI grade 
scale after PCI, was significantly lower. Multifactorial re-
gression analysis performed in the all-comers group of 
patients treated with PCI showed that PCI within CTO 
was related to higher CAP and lower overall complication 
rates. After PSM, CTO PCI was also significantly related 
to higher frequency of CAPs, and at the same time, lower 
frequency of deaths, no-reflow, dissections and overall 
periprocedural complication count. 
The increase in CAP rate among the all-comers PCI 
group in consecutive years for the analysed registry, al-
though remaining at a low level, is at least partially relat-
ed to the different type of operators, when compared to 
other reported studies. Usually, the published registries 
include well-experienced operators, while in the present 
report among high volume PCI CTO operators, we also 
included beginners, which may explain the increase in 
the frequency of CAPs in recent years. The increase in 
beginner rate seems to be gradual for the last few years. 
It is also not without significance that patients qualified 
for PCI, including PCI CTO, present increasingly complex 
lesions, and despite the increasingly advanced equip-
ment used in PCIs, there is a decreasing tendency in the 
total number of procedure-related complications, while 
the number of CAP remains at a constant level or even 
tends to increase depending on the group analysed in 
recent years. This was demonstrated in other registries 
published recently [15]. Low rates of CAPs in the as-
sessed groups of patients, in comparison to other regis-
tries, could be mainly explained by underestimation, due 
to the way of reporting them. Reporting CAPs were left 
to the operator’s decision, while in other registries, ad-
ditional core-lab analysis was performed, which delivers 
more precise results and usually elevates periprocedural 
complication rates. 
Overall complications
The overall complication rate decreased in all of 
the observed groups of patients (CTO PCI, non-CTO PCI 
and all-comers PCI); however, interestingly, CTO PCI was 
found to be a negative predictor of overall complication 
rate in the all-comers group before and after PSM. Also, 
the overall periprocedural complication rate was higher 
among non-CTO PCI patients than in the CTO PCI group, 
which was mainly due to significantly higher rates of CAP, 
no-reflow and puncture-site bleeding. 
It was reported in previously published studies that 
CAP, bleeding and contrast-induced nephropathy were 
more frequently observed in female patients [15, 16]. 
Female patients are under-represented in the published 
CTO PCI literature, with the proportion of female patients 
varying from 14% to 21%, while in our study, this totalled 
25% [16]. The study published by Riley et al. demonstrat-
ed that the overall complication rate in CTO PCIs was 
Figure 2. Frequency distribution of all coronary 
artery perforations in consecutive years between 
2014 and 2018 and selected groups of patients. 
A  – Overall group of patients treated with PCI.  
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Figure 3. A – Predictors of all periprocedural complications in the overall group of patients treated with PCI. 
B – Predictors of coronary artery perforation in the overall group of patients treated with PCI
CTO – chronic total occlusion, PCI – percutaneous coronary intervention, DES – drug-eluting stent, DCB – drug-coated balloon, POBA – plain-old balloon 
angioplasty, BRS – bioresorbable scaffold, BMS – bare-metal stent, TIMI – thrombolysis in myocardial infarction.
 OR 95% CI P-value 
Age [years] 1.017 1.015–1.019 < 0.001
Diabetes mellitus 1.098 1.041–1.159 < 0.001
Chronic obstructive pulmonary disease 1.220 1.077–1.382 0.002
Kidney disease 1.484 1.367–1.611 < 0.001
Smoking 1.209 1.140–1.281 < 0.001 
Femoral vs. radial vascular access 2.092 1.994–2.193 < 0.001 
Previous PCI 0.653 0.612–0.698 < 0.001 
Previous myocardial infarction 1.199 1.125–1.278 < 0.001 
Previous stroke 1.479 1.338–1.634 < 0.001 
TIMI flow grade before PCI 0 vs. others 3.038 2.890–3.193 < 0.001 
PCI with BMS vs. DES 1.803 1.613–2.014 < 0.001 
PCI with BMS vs. BRS 1.762 1.268–2.448 < 0.001 
PCI POBA/DCB/failed vs. DES 2.209 2.068–2.360 < 0.001 
PCI POBA/DCB/failed vs. BMS 1.225 1.083–1.385 0.001 
PCI POBA/DCB/failed vs. BRS 2.159 1.575–2.960 < 0.001 
Restenosis vs. de-novo culprit lesion 0.670 0.591–0.760 < 0.001 
Thrombosis vs. de-novo culprit lesion 1.298 1.078–1.563 0.005
Thrombosis vs. restenosis culprit lesion 1.936 1.565–2.395 < 0.001
CTO vs. non-CTO PCI 0.488 0.428–0.557 < 0.001
 OR 95% CI P-value 
Age [years] 1.0125 1.019–1.032 < 0.001
Kidney disease 1.327 1.049–1.678 0.018
Smoking 1.287 1.086–1.525 0.003
Previous stroke 1.552 1.174–2.053 0.002 
TIMI flow grade before PCI 0 vs. others 1.468 1.255–1.717 < 0.001 
No-reflow phenomenon 6.382 4.649–8.761 < 0.001 
PCI with BMS vs. DES 1.547 1.149–2.083 0.004 
PCI with BRS vs. DES 2.537 1.487–4.327 < 0.001 
PCI POBA/DCB/failed vs. DES 2.663 2.217–3.200 < 0.001 
PCI POBA/DCB/failed vs. BMS 1.721 1.239–2.391 0.001 
De-novo culprit lesion vs. thrombosis 2.587 0.959–6.977 0.06
CTO vs. non-CTO PCI 2.183 1.688–2.824 < 0.001
A
B
 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
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9.7% [1]. The most common adverse events were perfo-
ration (8.8%), MI (2.6%), arrhythmia requiring treatment 
(1.2%), cardiogenic shock (1.1%), and in-hospital deaths 
(0.9%). There were 9 procedure-related deaths (0.9%). All 
procedural deaths were associated with perforation and 
occurred among patients having undergone prior CABG 
surgery [1]. Independent predictors of complications 
during CTO PCI were: use of the retrograde approach, 
age and J-CTO score [1]. Prior analyses of CTO PCI com-
plication rates were mainly based on a  meta-analysis 
and data from the PROGRESS and RECHARGE registries. 
The meta-analysis reported a  pooled complication rate 
of 3.1% among 18,061 cases, similar to rates in non-
CTO PCI [11]. The PROGRESS registry demonstrated the 
overall periprocedural complication rates during hybrid 
CTO procedures of 2.8% from 1,569 cases. Complications 
reported included death (0.6%), MI (1.0%), emergent 
CABG (0.1%), stroke (0.3%), need for repeat PCI (0.3%) 
and tamponade from CAP requiring pericardiocentesis 
(1.0%) [17]. The RECHARGE is a similar contemporary Eu-
ropean registry reporting an overall complication rate of 
2.6%, with similar rates for death (0.2%), stroke (0.2%), 
MI (2.2%), major bleeding (1.9%) and tamponade (1.3%) 
[18]. In the study published by Riley et al., higher overall 
composite and constituent complication rates were re-
ported compared to both of the other registries as well 
as ours. The authors explained the differences as to how 
CAP rates were reported, and concluded that their anal-
ysis also included mild perforations (stage I of the Ellis 
classification), which could be mistakenly over-reported 
due to different method of assessing them [1]. In the 
study published by Riley, this was counted by a core-lab 
team based on cine angiographies [1].
Independent predictors of procedural complications 
were similar in previously reported data [19]. Older age 
and any use of the retrograde approach were associ-
ated with increased procedural risk [20]. However, Xe-
nogiannis et al. stated that in recent years, the rate of 
in-hospital MACE and mortality decreased in the group 
of patients treated with PCI within the CTO lesion and 
regarded in-hospital MACE (2% in the current era vs. 3% 
in the early era; p = 0.04), while for mortality decreased 
(0.2% in the current era vs. 0.7% in the early era; p = 
0.04) [21]. This was attributed, among other factors, to 
the decrease in CTO lesion complexity, lower rate of ret-
rograde crossing and antegrade dissection re-entry [21]. 
We do not possess such data for comparison. In contrast, 
patients undergoing CTO PCI were at more severe angina 
risk, while technical and procedural success rates remain 
high [21]. The mortality rate observed by Sapontis et al. 
was 0.9%, which is higher than previously reported in 
both hybrid and non-hybrid treated cohorts [19]. How-
ever, based on the data analysed in our analysis, even 
despite the PSM of the CTO PCI and non-CTO PCI groups, 
in the group of CTO PCI patients there were statistically 
significantly more patients with chronic coronary syn-
dromes (37.8% vs. 30.8%), and fewer with unstable angi-
na pectoris (30.0% vs. 32.3%), NSTEMI (19.2% vs. 17.4%) 
and STEMI (12.0% vs. 17.3%; p < 0.001). It resulted in 
a more severe average clinical condition of patients from 
the non-CTO PCI group at baseline, which was reflected 
in a higher percentage of cardiac arrests before admis-
sion to hospital (2.5% vs. 1.8%, p = 0.023).
Coronary artery perforations
The incidence of CAP in our cohort of patients was 
lower than that in a recent meta-analysis (2.9% to 4.3%) 
[11]. Also, compared to large real word registries, the 
frequency of CAPs was clearly lower in the analysis pre-
sented [15]. CTO PCI has been identified in previously 
published studies as a risk factor for CAP (OR: 3.96–14.7) 
[3, 9]. Other reported risk factors for CAP include older 
patient age, female gender, previous CABG and use of 
rotational as well as laser atherectomy [3, 9, 10, 16]. In 
the current analysis, we confirmed older age to be among 
the predictors of increased CAP frequency, apart from 
kidney disease, smoking, prior cerebral stroke, no-reflow 
phenomenon, type of PCI and culprit lesion as well as 
PCI within the CTO lesion. The strongest impact on the 
frequency of CAP was found for no-reflow, with the odds 
ratio of 6.382. 
The study published by Parsh et al., which included an 
overall group of patients treated with PCI, revealed that 
patients with CAP were older, more likely to be female, 
have peripheral arterial disease or heart failure, require 
an intra-aortic balloon pump or other mechanical ventric-
ular support prior to PCI, treatment of high complexity 
(type C) lesions, treatment of CTO and to be in cardio-
genic shock at the beginning of the procedure compared 
to those without CAP. Conversely, patients with perfora-
tions were less likely to have diabetes [3]. Similar patient 
and angiographic characteristics as potential risk factors 
for CAP including older age, female gender, presence of 
chronic kidney disease, arterial hypertension, and previ-
ous PCI or CABG as well as angiographic characteristics 
such as type C lesions, CTOs, calcified lesions and culprit 
lesions in the right coronary artery, have also been iden-
tified in other studies [4]. Some of them were confirmed 
by our results. It was further noted that treatment of CTO 
was the strongest risk factor for CAP development [3]. In 
our study, no-reflow was the strongest, while CTO was 
also found to be a strong predictor. It was also demon-
strated that the effect of CAP on mortality may be more 
deleterious in women than in men [11]. Among the sev-
eral explanations of that relationship, the leading ones 
are the smaller vessel diameter and differences in vessel 
wall thickness in women. Azzalini et al., in their multi-cen-
tre study performed on 1,811 patients treated with PCI 
within CTO, found the CAP rate to be 5.5%. CAPs required 
intervention in half of the cases, and led to tamponade in 
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1/5 patients. Approximately half of the perforations were 
due to injury to the CTO vessel and the other half were 
related to the retrograde approach. The highest burden of 
acute morbidity and mortality observed in patients who 
developed CTO vessel-related perforations was related to 
age, long occlusions and more advanced techniques (ro-
tational atherectomy, antegrade dissection/re-entry and 
retrograde approach) needing to cross complex occlu-
sions [22]. Patients with perforation suffered an increased 
incidence of target vessel failure during the short-term 
follow-up [22]. In a very large study (n = 26,807) carried 
out by Kinnaird et al., it was found that CAPs may have 
an effect on mortality, with an odds ratio for 12-month, 
all-cause mortality of 1.60 for perforation survivors com-
pared to matched subjects without CAP [7]. The authors 
attributed this to several possible explanations, such as 
incomplete revascularization due to procedure interrup-
tion secondary to perforation, concomitant complications 
(vascular complications, periprocedural MI, major bleed-
ing, etc.), and restenosis/thrombosis of covered stents. As 
reported by Parsh et al., CTO PCI is the strongest indepen-
dent predictor of developing CAP, being associated with 
a 7-fold increase in the adjusted risk of such a complica-
tion, compared to non-CTO PCI [3]. The aetiology of CAP in 
CTO PCI is multifaceted, and it can be related to the pres-
ence of severe calcification within the occlusion requiring 
aggressive plaque modification, proximal cap ambiguity 
and unclear vessel course, as well as the use of antegrade 
dissection/re-entry techniques and the retrograde ap-
proach, particularly through epicardial collaterals [23, 24].
Danek et al. reported in their study, performed on more 
than 2,049 patients treated with CTO, a CAP rate of 4.1%, 
and that CAP occurred more frequently in older patients 
and those with prior CABG [6]. They indicated the follow-
ing to be among phenomena related to the higher rate of 
CAPs: prior PCI, RCA target vessel and angiographic com-
plexity necessitating the use of advanced CTO crossing 
techniques [6]. Some of those factors were confirmed in 
our analysis. Sapontis et al., in a registry including 1,000 
consecutive patients, reported that CAPs requiring treat-
ment occurred in 4.8% of patients, and the overall perfora-
tion frequency was 8.8% [19]. When assessing type of the 
lesion, Sapontis et al. reported the frequency of de-novo 
lesions to be 89.3%, while the restenosis rate was 10.7%, 
and as reported in other studies, the right coronary artery 
was most commonly treated [19]. Similar percentages 
were observed in our registry with slightly lower frequen-
cies of restenosis. The risks of CTO PCI are reported to de-
crease over time and be similar to those of non-CTO PCI 
[11]. Perforations were observed by the core-lab in 8.8% 
of cases and were reported by operators in 6.6% of cases. 
The authors explain that this higher perforation frequency 
may relate to the implementation of core-lab assessment 
and the tendency for operators to not report clinically in-
significant perforations to avoid scrutiny [19].
Hirai et al., in a multi-centre registry including 1,000 
consecutive patients treated with CTO PCI, reported an 
in-hospital death rate among patients with CAP of 10.1%, 
whereas in our registry, procedure-related death was re-
ported in 1.1% of cases, while considering the CTO PCI 
group, this equalled 0.44%, and for the non-CTO PCI group 
0.45%. Hirai et al. reported that in their study, 55.8% of 
patients with CAPs had a history of prior CABG, while in 
our study, this was only true in 7.7% of patients [25].
In another study published by Danek et al., a peripro-
cedural complication rate of 2.8% was reported. In-hos-
pital complications included: death, MI, recurrent 
symptoms requiring urgent repeat target vessel revascu-
larization with PCI or CABG, tamponade requiring either 
pericardiocentesis or surgery and stroke [17]. It is clear 
that the study included only serious complications in 
comparison to our analysis. Danek et al. also confirmed 
older age as the most important predictor of complica-
tions [17]. This finding is consistent with our study and 
prior studies. It is likely related to more complex coronary 
anatomy with increasing age, higher prevalence of tortu-
osity, calcification, prior CABG and possibly, lower toler-
ance to inadvertent guidewire exits.
Limitations of our study include its retrospective, ob-
servational design, lack of core-laboratory adjudication, 
and limited follow-up. Relatively few coronary perfo-
rations were observed. There are several limitations to 
our study. First, our study was a  retrospective analysis 
utilising data from a large database which does not in-
clude details on the severity of CAP (such as Ellis type 
classification) or vessel size, which would be valuable to 
examine when attempting to identify the aetiology of the 
potentially worse CAP prognosis in women than men. In 
addition, various outcomes that may develop after CAP, 
including tamponade, need for emergency surgery or 
subsequent development of MI, could not be evaluated 
in our population based on database restrictions. One of 
the key factors that may be significantly related to the in-
cidence of CAP is the type of approach to CTO (antegrade 
vs. retrograde). Unfortunately, the database analysed by 
our team does not differentiate CTO procedures in this 
aspect and it is not possible to perform such an analysis, 
which eliminates the possibility of estimating one of the 
key factors that may affect the frequency of CAP occur-
rence and contributing to the bias analysis.
Conclusions
The main finding of the current study is that patients 
from the CTO PCI group presented significantly higher 
frequency of periprocedural complications and CAPs in 
comparison to the non-CTO PCI group. The frequency of 
overall periprocedural complications and CAPs has re-
mained stable in the CTO PCI group in recent years, while 
in the all-comers group, CAP rates significantly increased 
during the same period. Patients from the CAP CTO group 
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are significantly older, more often females and more fre-
quently treated from radial access in comparison to the 
non-CAP CTO group. PCI within CTO performed in the 
all-comers group is related to a higher CAP rate. Also, af-
ter matching, CTO PCI was significantly related to a high-
er frequency of CAPs. 
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